Theseus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	0.11	0.02	0.02	0.03	-
Revenue Growth (YoY)	500.00%	5.56%	-28.00%	-	-
Gross Profit	0.11	0.02	0.02	0.03	-
Selling, General & Admin	7.28	5.89	8.23	5.9	1.52
Operating Expenses	8.14	6.58	8.71	5.93	1.52
Operating Income	-8.03	-6.56	-8.69	-5.9	-1.52
Interest & Investment Income	0.25	0.46	-	-	-
EBT Excluding Unusual Items	-7.78	-6.1	-8.69	-5.9	-1.52
Asset Writedown	-	-0.24	-0.12	-	-
Pretax Income	-7.78	-6.34	-8.81	-5.9	-1.52
Net Income	-7.78	-6.34	-8.81	-5.9	-1.52
Net Income to Common	-7.78	-6.34	-8.81	-5.9	-1.52
Shares Outstanding (Basic)	162	162	162	132	84
Shares Outstanding (Diluted)	162	162	162	132	84
Shares Change (YoY)	-	-	22.60%	56.76%	-
EPS (Basic)	-0.05	-0.04	-0.05	-0.04	-0.02
EPS (Diluted)	-0.05	-0.04	-0.05	-0.04	-0.02
Free Cash Flow	-7.32	-5.27	-8.62	-4.85	-1.32
Free Cash Flow Per Share	-0.04	-0.03	-0.05	-0.04	-0.02
Gross Margin	100.00%	100.00%	100.00%	100.00%	-
Operating Margin	-7041.23%	-34536.84%	-48261.11%	-23608.00%	-
Profit Margin	-6826.32%	-33363.16%	-48944.44%	-23608.00%	-
Free Cash Flow Margin	-6421.93%	-27757.90%	-47888.89%	-19412.00%	-
EBITDA	-7.96	-6.5	-8.62	-5.89	-1.52
D&A For EBITDA	0.06	0.07	0.07	0.01	0
EBIT	-8.03	-6.56	-8.69	-5.9	-1.52

Updated Sep 26, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.